Subtype
Malignant Soft Tissue Neoplasm of Uncertain Differentiation
CI-CAN-00001179Explore in graph →
66 active trials2 approved drugs25 evidence items
- NCIt
- C6588
Loading cancer entity…
Subtype
CI-CAN-00001179Explore in graph →
Clinical trials
186 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (29)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06165718 | Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma. | unknown | — | 120 | China-Japan Friendship HospitalOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT03600649 | Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas | unknown | Phase 1 | 50 | Salarius Pharmaceuticals, LLCINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT05266196 | A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) | unknown | Phase 1 / Phase 2 | 10 | Salarius Pharmaceuticals, LLCINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05963035 | Clinical Application of 18F-PFPN PET Imaging in Diagnosis and Staging of Clear Cell Sarcoma of Soft Tissue | unknown | N/A | 10 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05617105 | Molecular Characterization of Perivascular Epithelioid Cell Tumors(PEComesCells) | unknown | — | 100 | University Hospital, Strasbourg, FranceOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT03623581 | Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226) | unknown | Phase 2 | 35 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT03989596 | Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas(SINDIR) | unknown | Phase 2 | 30 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT03651375 | Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall(UN-RESARC) | unknown | Phase 2 | 46 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT02968303 | Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy(COWBOY) | unknown | Phase 2 | 200 | Radboud University Medical CenterOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT01337401 | A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)(CASPS) | unknown | Phase 2 | 36 | Institute of Cancer Research, United KingdomOTHER | 3 | Jan 24, 2019 | clinicaltrials |
| NCT02983539 | Detection of Circulating Tumor Cells in Patients With Sarcomas(CTCS) | unknown | — | 20 | AC Camargo Cancer CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02982486 | A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma | unknown | Phase 2 | 60 | Assaf-Harofeh Medical CenterOTHER_GOV | 0 | Nov 1, 2017 | clinicaltrials |
| NCT02834169 | French National Registry of Rare Peritoneal Surface Malignancies(RENAPE) | unknown | — | 2,171 | Hospices Civils de LyonOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Dec 15, 2023source: clinicaltrials